Previous 10 | Next 10 |
2024-06-04 05:29:00 ET Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock. Shares of Pfizer have been beaten severely in response to sinking sales of Comirnaty...
2024-06-04 04:20:17 ET Summary Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3...
2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...
2024-06-03 14:24:35 ET More on Pfizer, Takeda Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Pfizer: Down To A Historically Low Valuation - Is It A Buy? Takeda gets positive opinion from EU regulat...
2024-06-03 14:14:05 ET Summary BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for ...
2024-06-03 13:03:00 ET Summary Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expec...
2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...
2024-06-02 09:02:22 ET Summary The 50 largest companies on the Fortune 500 list accounted for nearly half of the total revenue and earnings. Four stocks from the Fortune 500 list were identified as ideal for first-time investors due to their high dividends. Analysts estimated ...
2024-06-01 17:52:36 ET More on Corbus Pharmaceuticals Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets Seeking Alpha’s Quant Rating on Corbus Pharmaceutical...
2024-06-01 11:05:00 ET More on GSK, Pfizer GSK wins first Zantac cancer jury trial (updated) GSK faces another Zantac whistleblower lawsuit GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Tu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...